Yarrow Bioscience (YARW) Cash from Investing Activities (2017 - 2026)

Yarrow Bioscience (YARW) has 10 years of Cash from Investing Activities data on file, last reported at $4.7 million in Q1 2026.

• Quarterly Cash from Investing Activities fell 76.3% year-over-year to $4.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.9 million (down 10.31% YoY) and the FY2025 annual result came in at $37.4 million, up 59.93% from the prior year.
• Cash from Investing Activities improved to $4.7 million in Q1 2026, from $4.7 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $19.8 million in Q1 2025 to a low of -$62.4 million in Q4 2023.
• A 5-year average of $907000.0 and a median of $4.7 million in 2025 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2023 — Cash from Investing Activities plunged 6235500.0% — and 2025, when it surged 655.65%.
• Tracing YARW's Cash from Investing Activities over 5 years: stood at $1000.0 in 2022, then sank by 6235500.0% to -$62.4 million in 2023, then soared by 120.43% to $12.7 million in 2024, then tumbled by 63.3% to $4.7 million in 2025, then grew by 0.53% to $4.7 million in 2026.
• The last three Cash from Investing Activities figures came in at $4.7 million (Q1 2026), $4.7 million (Q2 2025), and $19.8 million (Q1 2025), per Business Quant data.